Giuseppe Pantaleo
Overview
Explore the profile of Giuseppe Pantaleo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
323
Citations
9602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Georgakis S, Ioannidou K, Mora B, Orfanakis M, Brenna C, Muller Y, et al.
Front Immunol
. 2025 Mar;
16:1530327.
PMID: 40070830
Introduction: Systemic lupus erythematosus (SLE) is characterized by dysregulated humoral immunity, leading to the generation of autoreactive B cells that can differentiate both within and outside of lymph node (LN)...
2.
Wright R, Sciara S, Pantaleo G
Behav Brain Sci
. 2025 Jan;
48:e48.
PMID: 39886887
Murayama and Jach critically evaluate the idea that motivation is a dynamic that determines behavior and propose alternatively that it might be an emergent property that people construe through perceived...
3.
Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8 T cells
Nguema L, Picard F, El Hajj M, Dupaty L, Fenwick C, Cardinaud S, et al.
EBioMedicine
. 2024 Dec;
111():105479.
PMID: 39667270
Background: Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane. Methods: Herein,...
4.
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, et al.
EClinicalMedicine
. 2024 Dec;
77:102845.
PMID: 39649135
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.Env is an innovative antigen delivery targeting gp140 Env from HIV Clade C 96ZM651 to CD40-expressing antigen-presenting cells, thus...
5.
Iwanek Nee Wilczkowska E, Liotta L, Pantaleo G, Hu L, Williams S, Kirk D, et al.
ACS Mater Au
. 2024 Nov;
4(6):643-653.
PMID: 39554856
Herein, we present a paper that attempts to bridge the gap between CO oxidation catalytic tests performed in a model stream and a more realistic exhaust gas stream by incorporating...
6.
Georgakis S, Orfanakis M, Brenna C, Burgermeister S, Del Rio Estrada P, Gonzalez-Navarro M, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39204036
Follicular helper CD4 T cells (T) are a major cellular pool for the maintenance of the HIV reservoir. Therefore, the delineation of the follicular (F)/germinal center (GC) immune landscape will...
7.
Beyrer C, Tomaras G, Gelderblom H, Gray G, Janes H, Bekker L, et al.
Lancet HIV
. 2024 Jun;
11(7):e489-e494.
PMID: 38925732
Rates of new HIV acquisition remain unacceptably high in most populations in low-income, middle-income, and high-income settings despite advances in treatment and prevention strategies. Although biomedical advances in primary prevention...
8.
Garrett N, Dintwe O, Monaco C, Jones M, Seaton K, Church E, et al.
J Acquir Immune Defic Syndr
. 2024 Jun;
96(4):350-360.
PMID: 38916429
Background: An effective vaccine is required to end the HIV pandemic. We evaluated the safety and immunogenicity of a DNA (DNA-HIV-PT123) vaccine with low- or high-dose bivalent (TV1.C and 1086.C...
9.
Mosmann T, Rebhahn J, De Rosa S, Keefer M, McElrath M, Rouphael N, et al.
Front Immunol
. 2024 Jun;
15:1347926.
PMID: 38903517
Introduction: The HVTN 105 vaccine clinical trial tested four combinations of two immunogens - the DNA vaccine DNA-HIV-PT123, and the protein vaccine AIDSVAX B/E. All combinations induced substantial antibody and...
10.
Testoni S, Pantaleo G, Contu F, Azzolini F, Fanti L, Testoni P
Dig Endosc
. 2024 May;
36(11):1232-1244.
PMID: 38818692
Objectives: We compared the efficacy and safety of transoral incisionless fundoplication (TIF) with the EsophyX2.0 and MUSE systems for treatment of gastroesophageal reflux disease (GERD). Methods: TIF outcomes from prospective...